Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0359 in Rheumatoid Arthritis
NCT00482417Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2002
- Primary completion
- May 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing MK0359 Arm with Placebo Arm (2 arms). Primary endpoint: American College of Rheumatology 20% Improvement at 12 weeks. Started Dec 2002; status: completed.
02
Drugs
MK-0359
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00482417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482417.